Odevixibat
Brand names: Bylvay · Active ingredient: Odevixibat
In short: BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC. Limitations of Use BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) prot
What is Odevixibat used for?
BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC.
Limitations of Use
BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) protein .
BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.
Odevixibat dosage
The recommended dosage of BYLVAY is 40 mcg/kg taken orally once daily in the morning with a meal. Table 1 below shows the recommended once daily dosage by body weight.
If there is no improvement in pruritus after 3 months, the dosage may be increased in 40 mcg/kg increments up to 120 mcg/kg once daily not to exceed a daily dosage of 6 mg/day.
BYLVAY oral pellets are intended for use by patients weighing less than 19.5 kilograms.
BYLVAY capsules are intended for use by patients weighing 19.5 kilograms or above.
Body Weight (kg) | Once Daily Dosage (mcg)
7.4 and below | 200
7.5 to 12.4 | 400
12.5 to 17.4 | 600
17.5 to 25.4 | 800
25.5 to 35.4 | 1,200
35.5 to 45.4 | 1,600
45.5 to 55.4 | 2,000
55.5 and above | 2,400
The recommended dosage of BYLVAY is 120 mcg/kg taken orally once daily in the morning with a meal. Table 2 below shows the recommended once daily dosage by body weight.
BYLVAY oral pellets are intended for use by patients weighing less than 19.5 kilograms.
BYLVAY capsules are intended for use by patients weighing 19.5 kilograms or above.
Body Weight (kg) | Once Daily Dosage (mcg)
7.4 and below | 600
7.5 to 12.4 | 1,200
12.5 to 17.4 | 1,800
17.5 to 25.4 | 2,400
25.5 to 35.4 | 3,600
35.5 to 45.4 | 4,800
45.5 to 55.4 | 6,000
55.5 and above | 7,200
Tolerability for Alagille Syndrome (ALGS)
Dose reduction to 40 mcg/kg/day (Table 1) may be considered if tolerability issues occur in the absence of other causes. Once tolerability issues stabilize, increase to 120 mcg/kg/day.
Liver Test Abnormalities
Establish the baseline pattern of variability of liver tests prior to starting BYLVAY, so that potential signs of liver injury can be identified. Monitor liver tests (e.g., ALT [alanine aminotransferase], AST [aspartate aminotransferase], TB [total bilirubin], DB [direct bilirubin] and International Normalized Ratio [INR]) during treatment with BYLVAY. Interrupt BYLVAY if new onset liver test abnormalities occur or symptoms consistent with clinical hepatitis are observed .
Once the liver test abnormalities either return to baseline values or stabilize at a new baseline value, consider restarting BYLVAY at the recommended dosage . Consider discontinuing BYLVAY permanently if liver test abnormalities recur.
Discontinue BYLVAY permanently if a patient experiences a hepatic decompensation event (e.g., variceal hemorrhage, ascites, hepatic encephalopathy).
For patients taking bile acid binding resins, take BYLVAY at least 4 hours before or 4 hours after taking a bile acid binding resin .
Do not crush or chew capsules.
Oral Pellets:
Mix the contents of the shell containing Oral Pellets into soft food or a liquid (as described below).
Discard the emptied shells. Do not let your child swallow the unopened shells containing the Oral Pellets. …
How to take Odevixibat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Instructions for Use).
Administration Instructions
Advise patients or their caregivers(s) to:
Take BYLVAY in the morning with a meal. Do not swallow the 200 mcg or 600 mcg capsule(s) containing Oral Pellets whole. These are intended to be opened and the contents mixed into soft food or liquids .
Follow stepwise administration Instructions for Oral Pellets and Capsules for patients unable to swallow the capsules whole.
Take BYLVAY at least 4 hours before or 4 hours after taking a bile acid binding resin (e.g., cholestyramine, colesevelam, or colestipol) .
Hepatotoxicity
Advise patients or their caregiver(s) that liver tests should be obtained before starting BYLVAY and periodically during BYLVAY therapy. Inform patients or their caregiver(s) of the potential risk of hepatotoxicity, and that they will need to undergo monitoring for liver injury. Instruct patients or their caregiver(s) to immediately report any signs or symptoms of severe liver injury to their healthcare provider .
Diarrhea
Advise patients or their caregiver(s) to notify their healthcare provider if they experience new onset or worsening of diarrhea . …
Warnings & precautions
Do not take this medicine if: IBAT inhibitors, including BYLVAY, are contraindicated in patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy) .
BYLVAY treatment is associated with a potential for drug-induced liver injury (DILI).
In the PFIC and ALGS trials, treatment-emergent elevations of liver tests or worsening of liver tests occurred. Of the six patients who experienced DILI, two underwent liver transplant.
Obtain baseline liver tests because some ALGS and PFIC patients have abnormal liver tests at baseline. Monitor patients frequently for the first 6 to 8 months after starting therapy and as clinically indicated thereafter during treatment with BYLVAY. Monitor for elevation in liver tests, for the development of liver-related adverse reactions, and for physical signs of hepatic decompensation. If liver test abnormalities or signs of clinical hepatitis occur in the absence of other causes, consider dose reduction or treatment interruption.
Permanently discontinue BYLVAY if a patient experiences the following:
persistent or recurrent liver test abnormalities, or
upon rechallenge, signs and symptoms consistent with clinical hepatitis, or
a hepatic decompensation event.
The safety and effectiveness of BYLVAY have not been established in patients with decompensated cirrhosis. Monitor patients with compensated cirrhosis or portal hypertension more frequently and discontinue BYLVAY if hepatic decompensation occurs. IBAT inhibitors, including BYLVAY, are contraindicated in patients with prior or active hepatic decompensation events .
In Trial 1, diarrhea in PFIC patients was reported in 2 (10%) placebo-treated patients, 9 (39%) BYLVAY-treated 40 mcg/kg/day patients and 4 (21%) BYLVAY-treated 120 mcg/kg/day patients. …
Odevixibat side effects
The following adverse reactions are discussed in greater detail in other sections of the label:
Hepatotoxicity
Diarrhea
Fat-Soluble Vitamin Deficiency
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
PFIC Clinical Studies
Trial 1 is a randomized, double-blind, placebo-controlled, 24-week study of two dose levels of BYLVAY (40 mcg/kg and 120 mcg/kg) administered once daily . Sixty-two patients were randomized (1:1:1) to receive one of the following:
BYLVAY 40 mcg/kg/day (n=23),
BYLVAY 120 mcg/kg/day (n=19), or
Placebo (n=20).
Table 3 summarizes the frequency of adverse reactions reported in ≥2% and at a rate greater than placebo in patients treated with BYLVAY in Trial 1. The most common adverse reactions observed in Trial 1 included diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. …
Drug interactions
Administer bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol) at least 4 hours before or 4 hours after administration of BYLVAY . Bile acid binding resins may bind odevixibat in the gut, which may reduce BYLVAY efficacy.
About this medicine
The active ingredient in BYLVAY (odevixibat) capsules and BYLVAY (odevixibat) oral pellets, an ileal bile acid transporter (IBAT) inhibitor, is (2S)-2-{[(2R)-2-(2-{[3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1λ6,2,5-benzothiadiazepin-8yl]oxy}acetamido)-2-(4-hydroxyphenyl)acetly]amino}butanoic acid, which is formulated as the sesquihydrate having the following chemical structure:
The molecular formula is C37H48N4O8S2 × 1.5 H2O, with a molecular weight of 768.0 g/mol (anhydrous 740.9 g/mol). Odevixibat sesquihydrate is a white to off-white solid. Its solubility in aqueous solutions is pH-dependent and increases with increased pH.
BYLVAY is available for oral administration as oral pellets containing odevixibat sesquihydrate equivalent to 200 mcg or 600 mcg of odevixibat, and as capsules containing odevixibat sesquihydrate equivalent to 400 mcg or 1200 mcg of odevixibat, and the following excipients: hypromellose and microcrystalline cellulose.
The capsule shells for the oral pellets contain hypromellose, titanium dioxide and yellow iron oxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0935cd31-3251-4a0a-ac23-25ca4be12be9. Read the full official label on DailyMed.